Jane Street’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.6M | Sell |
194,800
-20,700
| -10% | -$1.71M | ﹤0.01% | 2015 |
|
|
2025
Q4 | $18.4M | Sell |
215,500
-14,800
| -6% | -$1.21M | ﹤0.01% | 1694 |
|
|
2025
Q3 | $17.9M | Buy |
230,300
+128,000
| +125% | +$10M | ﹤0.01% | 1759 |
|
|
2025
Q2 | $8M | Sell |
102,300
-66,600
| -39% | -$4.97M | ﹤0.01% | 2421 |
|
|
2025
Q1 | $12.2M | Sell |
168,900
-171,300
| -50% | -$12.3M | ﹤0.01% | 1754 |
|
|
2024
Q4 | $25.2M | Sell |
340,200
-3,194,700
| -90% | -$224M | 0.01% | 1105 |
|
|
2024
Q3 | $233M | Buy |
3,534,900
+3,331,800
| +1,640% | +$242M | 0.05% | 196 |
|
|
2024
Q2 | $18.8M | Sell |
203,100
-35,700
| -15% | -$3.16M | ﹤0.01% | 1371 |
|
|
2024
Q1 | $22.8M | Sell |
238,800
-40,400
| -14% | -$3.39M | ﹤0.01% | 1093 |
|
|
2023
Q4 | $21.3M | Buy |
279,200
+149,900
| +116% | +$10.4M | 0.01% | 1220 |
|
|
2023
Q3 | $8.96M | Sell |
129,300
-7,400
| -5% | -$595K | ﹤0.01% | 1896 |
|
|
2023
Q2 | $12.9M | Sell |
136,700
-41,300
| -23% | -$3.59M | ﹤0.01% | 1648 |
|
|
2023
Q1 | $14.7M | Buy |
178,000
+79,300
| +80% | +$6.23M | 0.01% | 1258 |
|
|
2022
Q4 | $7.36M | Sell |
98,700
-13,800
| -12% | -$1.06M | ﹤0.01% | 1972 |
|
|
2022
Q3 | $9.3M | Sell |
112,500
-33,000
| -23% | -$3.18M | ﹤0.01% | 1768 |
|
|
2022
Q2 | $13.8M | Sell |
145,500
-61,500
| -30% | -$6.37M | 0.01% | 1424 |
|
|
2022
Q1 | $24.4M | Buy |
207,000
+63,500
| +44% | +$7.12M | 0.01% | 1104 |
|
|
2021
Q4 | $18.6M | Sell |
143,500
-99,000
| -41% | -$11.5M | 0.01% | 1271 |
|
|
2021
Q3 | $27.5M | Sell |
242,500
-219,800
| -48% | -$25.1M | 0.01% | 920 |
|
|
2021
Q2 | $47.9M | Buy |
462,300
+321,300
| +228% | +$30.3M | 0.02% | 570 |
|
|
2021
Q1 | $11.8M | Buy |
141,000
+26,400
| +23% | +$2.23M | 0.01% | 1399 |
|
|
2020
Q4 | $10.5M | Sell |
114,600
-19,500
| -15% | -$1.62M | 0.01% | 1378 |
|
|
2020
Q3 | $10.7M | Buy |
134,100
+49,700
| +59% | +$3.88M | 0.01% | 1162 |
|
|
2020
Q2 | $5.83M | Sell |
84,400
-81,800
| -49% | -$5.81M | ﹤0.01% | 1683 |
|
|
2020
Q1 | $10.4M | Buy |
166,200
+66,000
| +66% | +$4.76M | 0.01% | 745 |
|
|
2019
Q4 | $7.79M | Buy |
100,200
+48,600
| +94% | +$3.79M | 0.01% | 776 |
|
|
2019
Q3 | $3.78M | Sell |
51,600
-38,100
| -42% | -$2.68M | 0.01% | 1209 |
|
|
2019
Q2 | $5.52M | Sell |
89,700
-17,100
| -16% | -$1.03M | 0.01% | 978 |
|
|
2019
Q1 | $6.81M | Buy |
106,800
+65,100
| +156% | +$3.72M | 0.01% | 926 |
|
|
2018
Q4 | $2.13M | Sell |
41,700
-50,400
| -55% | -$2.55M | ﹤0.01% | 1661 |
|
|
2018
Q3 | $5.34M | Buy |
92,100
+63,300
| +220% | +$3.1M | 0.01% | 991 |
|
|
2018
Q2 | $1.4M | Sell |
28,800
-41,400
| -59% | -$1.93M | ﹤0.01% | 2348 |
|
|
2018
Q1 | $3.27M | Buy |
+70,200
| New | +$3.05M | 0.01% | 1330 |
|
|
2017
Q4 | – | Sell |
-21,600
| Closed | -$787K | – | 4715 |
|
|
2017
Q3 | $787K | Buy |
21,600
+6,300
| +41% | +$240K | ﹤0.01% | 2551 |
|
|
2017
Q2 | $603K | Buy |
15,300
+5,400
| +55% | +$197K | ﹤0.01% | 2784 |
|
|
2017
Q1 | $310K | Buy |
9,900
+600
| +6% | +$18.8K | ﹤0.01% | 3403 |
|
|
2016
Q4 | $290K | Sell |
9,300
-38,100
| -80% | -$1.23M | ﹤0.01% | 3392 |
|
|
2016
Q3 | $1.91M | Buy |
47,400
+30,900
| +187% | +$1.16M | 0.01% | 1254 |
|
|
2016
Q2 | $549K | Sell |
16,500
-39,900
| -71% | -$1.37M | ﹤0.01% | 2671 |
|
|
2016
Q1 | $1.66M | Buy |
+56,400
| New | +$1.56M | 0.01% | 1356 |
|
Other funds holding EW
VCM
VPM
Jane Street's EW Position: Q1 2026 in Review
Jane Street reduced its Edwards Lifesciences (EW) stake by 34% in Q1 2026, selling an estimated $16.6M and leaving 390,333 shares worth $31.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1407.
Jane Street first reported a position in EW in Q1 2014 and has held it in 45 quarters since. The position peaked at $121M in Q3 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Jane Street held 390,333 shares of Edwards Lifesciences worth $31.3M as of Q1 2026.
- Jane Street sold 201,167 Edwards Lifesciences shares in Q1 2026, an estimated $16.6M.
- Edwards Lifesciences made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1407 holding.
- Jane Street first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 45 quarters since.
- Jane Street's Edwards Lifesciences position peaked at $121M in Q3 2025.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.